Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Regeneron Pharmaceuticals Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.53 (market cap $2.14B), while Regeneron Pharmaceuticals Inc trades at $797 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 38.3× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.47%). Which is the better fit depends on your goals.
| AMC | REGN | |
|---|---|---|
Market Cap | $2.14B | $82.06B |
Sector | Media | Health |
52-Week High | $3.15 | $812.27 |
52-Week Low | $0.95 | $555.51 |
Enterprise Value | $9.08B | $76.77B |
Dividend Yield | 0.11% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.555, up 5.58% today, with a bullish technical signal and recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by strong box office performance and premium screen growth. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion as of 2024. Cash flow trends show improvement, with projected positive operating cash flow of $219 million in 2026.
Outlook is mixed; operational recovery and analyst consensus price target of $3.00 offer upside, but high debt and persistent losses pose significant risks. Investor sentiment is buoyed by record-breaking weekends and international expansion, yet volatility from meme-stock status and competitive pressures require caution.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
